Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release ...

Onco-Innovations Limited: Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor ...

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release date ...
PharmiWeb

CellProthera Collaborates with Quintessence Biotech to Industrialize Cell Manufacturing Processes Ahead of Stroke Clinical Trials

CellProthera will use Quintessence’s DACSTM flotation‑based cell sorting platform for its potential to enhance therapeutic purity and preserve stem cell phenotype for CD34+-based cell therapy Mulhouse ...
The Manila Times

ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery

From April 17 to 22, 2026, ACROBiosystems-a company dedicated to being a cornerstone of the global biopharmaceutical and ...
AZoM

Environmental Monitoring in ATMP Manufacturing Facilities

Environmental monitoring requirements in ATMP facilities, addressing regulatory compliance, GMP standards, and contamination ...
Contract Pharma

Engineering Flexibility into Modern CDMO Manufacturing

Eduard Viladesau, Managing Director, HIPRA Biotech Services, highlights how the company brings engineered flexibility to the ...

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

The MSA includes the technology transfer of the REYOBIQ manufacturing process, Rhenium-186 isotope processing, analytical methods, as well as technical and regulatory expertise supporting future ...
TMCnet

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first ...
Vietnam Investment Review on MSN

Minaris achieves perfect manufacturing record for CAR T program

PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
Malaysia Sun

Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CART Program

Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, ...

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing ...

HYTN Introduces HARd Remediation to GMP Processing Services, Releases Product in Germany

HARd is HYTN’s proprietary remediation process for dried cannabis flower, developed and validated within the Company’s GMP quality systems. The process is designed to reduce microbial burden while ...